A Phase II Open Label, Single Arm Study to Evaluate the Efficacy of Pembrolizumab for Leukoplakia
Phase of Trial: Phase II
Latest Information Update: 02 Jul 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Erythroleucoplakia; Leucoplakia
- Focus Therapeutic Use
- 26 Jun 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 Planned End Date changed from 1 Dec 2021 to 1 Jun 2022.
- 26 Feb 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2021.